January 30, 2022 · 7:00 PM
Semaglutide and liraglutide are medicine that have been developed to deal with diabetes and are FDA-approved for that. They are given by subcutaneous injection. Semaglutide can also be FDA-approved for weight loss in non-diabetics if sure situations are met.
Once-weekly semaglutide outperformed each day liraglutide in obese and overweight non-diabetics.
From JAMA Network:
Question Among adults with obese or weight problems with out diabetes, what’s the impact of once-weekly subcutaneous semaglutide, 2.4 mg, vs once-daily subcutaneous liraglutide, 3.0 mg, on weight loss when every is added to counseling for food regimen and bodily exercise?
Findings In this randomized medical trial that included 338 contributors, imply body weight change from baseline to 68 weeks was –15.8% with semaglutide vs –6.4% with liraglutide, a statistically vital distinction.
Meaning Among adults with obese or weight problems with out diabetes, once-weekly subcutaneous semaglutide, in contrast with once-daily subcutaneous liraglutide, added to counseling for food regimen and bodily exercise resulted in considerably higher weight loss at 68 weeks.
For prevention or enchancment of overweight- and obesity-related diseases, intention for loss of a minimum of 5 to 10% of body weight. Assuming you’re obese or overweight within the first place. 16% body weight change is critical. 16% of 300 kilos (136 kg) can be 48 kilos (22 kg).
Steve Parker, M.D.
PS: My e-book’s inexpensive than these medicine. And no needles!